LCTX LINEAGE CELL THERAPEUTICS IN
FollowCOMMON STOCK (common), issuer CIK 876343
Filings received so far for Q3 2026: 5 13F filers report a position in LCTX shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.
Insider trades
No Form 4 transaction on this security in the data.
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
| Holder | Shares | Value | % of portfolio | Change | Source |
|---|---|---|---|---|---|
| Defender Capital, LLC. | 6,648,899 | $6.35M | 1.99% | +50,000 | 13F-HRTimeline |
| CHAPIN DAVIS, INC. | 20,000 | $19.1K | <0.01% | -29 | 13F-HRTimeline |
| Pacifica Partners Inc. | 2,926 | $2.63K | <0.01% | 0 | 13F-HRTimeline |
| GAMMA Investing LLC | 2,273 | $2.17K | <0.01% | new | 13F-HRTimeline |
| Farther Finance Advisors, LLC | 1,126 | $1.08K | <0.01% | +582 | 13F-HRTimeline |